On May 24th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dimension Therapeutics, Inc. for the development of an Adeno-Associated Virus Vectors for the Treatment of Glycogen… Continue Reading
On May 19th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to IntelliPanel Medical, LLC. for Anti-TNF Induced Apoptosis (ATIA) Diagnostic Markers and Therapies. Below are the comments… Continue Reading
Reports have emerged from a DNDi meeting in Rio de Janeiro, Brazil, that the Colombian Ministry of Health announced that negotiations with Novartis over the price of Glivec have failed, and that Minister Alejandro Gaviria will proceed with the formal declaration that a compulsory license for the patents on the drug is in the public interest.
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On May 24th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dimension… Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On May 19th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Etubics… Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On May 19th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to IntelliPanel… Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On May 18th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dimension… Continue Reading
Yesterday, Colombia’s W Radio aired an interview with Senator Orrin Hatch, R-Utah, where he was asked about the reports of pressure on Colombia from the Senate Finance Committee, which he chairs, with regard to the compulsory license process for the expensive leukemia drug, imatinib.
(More on Colombia here: /colombia) For more information, contact: (U.S.) Andrew Goldman, KEI: andrew.goldman@keionline.org or +1 (202) 332-2670 (Colombia) Andrea Carolina Reyes Rojas, Misión Salud: subdireccion@mision-salud.org (Colombia) Dr. Francisco Rossi, IFARMA: francisco_rossi@hotmail.com Frequently Asked Questions What is happening in Colombia… Continue Reading
Attached is a letter that KEI, Public Citizen, Oxfam America and Health GAP have sent to Senator Hatch, via the Senate Finance Committee, objecting to the pressure his office has put on Colombia over a compulsory license on patents held by Novartis for the cancer drug Gleevec. This refers to the accounts of pressure from Hatch’s office that are described in two letters from the Colombia Embassy in Washington, dated April 27 and April 28, which were recently leaked. Continue Reading